LivaNova (LIVN) – Investment Analysts’ Weekly Ratings Changes

LivaNova (NASDAQ: LIVN) recently received a number of ratings updates from brokerages and research firms:

• 5/13/2025 – LivaNova had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $64.00 price target on the stock.
• 5/8/2025 – LivaNova had its price target raised by analysts at Robert W. Baird from $55.00 to $61.00. They now have an “outperform” rating on the stock.
• 5/8/2025 – LivaNova had its price target lowered by analysts at Barclays PLC from $56.00 to $55.00. They now have an “equal weight” rating on the stock.
• 5/8/2025 – LivaNova was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.
• 3/25/2025 – LivaNova was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.

LivaNova Stock Down 1.0%

Shares of NASDAQ:LIVN opened at $43.97 on Tuesday. The stock has a market cap of $2.40 billion, a P/E ratio of 104.69 and a beta of 0.84. The firm has a fifty day moving average price of $38.49 and a 200 day moving average price of $44.76. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $62.04.

Institutional Investors Weigh In On LivaNova

A number of hedge funds and other institutional investors have recently modified their holdings of the company. KBC Group NV boosted its position in shares of LivaNova by 130.5% in the fourth quarter. KBC Group NV now owns 99,928 shares of the company’s stock worth $4,628,000 after acquiring an additional 56,580 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in LivaNova by 29.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company’s stock valued at $292,000 after buying an additional 1,424 shares in the last quarter. Rhumbline Advisers lifted its position in LivaNova by 0.5% during the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company’s stock valued at $8,240,000 after buying an additional 899 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in LivaNova during the fourth quarter valued at approximately $2,772,000. Finally, Envestnet Asset Management Inc. lifted its position in LivaNova by 15.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company’s stock valued at $2,034,000 after buying an additional 5,850 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.